Daniel Spratt Laboratory

The Spratt laboratory is focused on understanding the interplay and crosstalk between androgen receptor (AR) signaling and DNA repair in prostate cancer. A fundamental method of treatment in men with prostate cancer is with ionizing radical radiotherapy. Oncologic results have been significantly improved from the addition of AR inhibition to radiotherapy through reduction in ligand (testosterone) or receptor blockade. Our lab focuses on understanding why AR inhibition improves clinical outcomes. Early data from our lab suggests that DNA repair pathways are significantly altered after AR directed therapy, and can lead to functional radiosensitization. We are primarily interested in understanding how this process occurs and how to optimally combine AR directed therapies with radiotherapy.

A second focus of the Spratt lab is to develop and characterize prognostic and predictive biomarkers to personalize treatment for men with prostate cancer. Most of the work is directed at utilizing gene expression data and non-invasive imaging to better understand the aggressiveness and treatment response of a specific therapy.


  • AR signaling and DNA repair interplay in prostate cancer
  • Development of prognostic and predictive genomic biomarkers to guide treatment in prostate cancer

Join US:

Please contact Daniel Spratt MD if you are interested in working for or collaborating with the Spratt Lab.

Laboratory Lead

Daniel Spratt

Daniel Spratt, MD

Laurie Snow Research Professor of Radiation Oncology
Associate Chair, Clinical Research
Chair, Genitourinary Clinical Research, Rogel Cancer Center
Director, Spine Oncology Program, Rogel Cancer Center